Cargo Therapeutics logo

Cargo Therapeutics

San Carlos, CA, USA Biotech & Pharma Public

Cargo Therapeutics is a clinical-stage biopharmaceutical company focused on designing, engineering, and developing potentially curative next-generation cell therapies for cancer patients. The company's platform technologies and manufacturing strategy are designed to address limitations of approved cell therapies, including limited durability of effect, safety concerns, and availability.

Public Company

Cargo Therapeutics is publicly traded

IPO'd on November 10, 2023

CRGX NASDAQ

This company is no longer available on our private secondary market. Shares can be traded publicly under CRGX.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2019

Employees

76–167

Total Funding

$492M

3 rounds

Funding

Total raised $492M across 3 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 06-25-2026

Latest Round

Type

IPO

Date

November 10, 2023

Amount

$281M

Valuation

Lead Investors

Public markets
DateRoundAmount RaisedValuationLead Investors
November 10, 2023 IPO $281M Public markets
March 1, 2023 Series A $200M Third Rock Ventures, RTW Investments, Perceptive Xontogeny Venture Fund
2021 Seed $11M Samsara BioCapital

Prominent Investors

T. Rowe Price Cormorant Asset Management Wellington Management Ally Bridge Group Janus Henderson Investors Nextech Perceptive Xontogeny Venture Fund RTW Third Rock Ventures Piper Heartland

Leadership

  • Crystal Mackall

    Co-Founder

  • Nancy Goodman

    Co-Founder

  • Robbie Majzner

    Co-Founder, Chief Medical Officer

  • Louai Labanieh

    Co-Founder

  • Gina Chapman

    Chief Executive Officer (departed March 2025)

    LinkedIn
  • Anup Radhakrishnan

    Interim Chief Executive Officer (appointed March 2025)

  • Halley Gilbert

    Chief Legal Officer

Cargo Therapeutics Investment FAQ

Cargo Therapeutics FAQ

Yes, Cargo Therapeutics is publicly traded under the ticker symbol CRGX on the NASDAQ. The company went public in November 10, 2023.

Cargo Therapeutics trades under the ticker symbol CRGX on the NASDAQ. It began trading in November 10, 2023.

Cargo Therapeutics (CRGX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CRGX to place an order.

Cargo Therapeutics went public in November 10, 2023 via ipo. CARGO Therapeutics went public on NASDAQ (CRGX) on November 10, 2023, pricing 18.75M shares at $15/share, raising $281M. The company was subsequently acquired by Concentra Biosciences on July 8, 2025, for $4.379 per share in cash plus contingent value rights, following clinical setbacks with its lead CAR-T therapy candidate Firi-cel.

Cargo Therapeutics raised $492M across 3 disclosed funding rounds prior to its public listing.

Cargo Therapeutics was co-founded by Crystal Mackall, Nancy Goodman, Robbie Majzner, and 1 others in 2019.

Cargo Therapeutics is headquartered in San Carlos, CA, USA.

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.